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Available online 21 October 2016Mutations in KIT or PDGFRA are responsible for N85% of gastrointestinal stromal tumors. The introduction of
imatinib in the GIST therapy scheme revolutionized the patient outcome. Unfortunately, the therapy allows
the disease stabilization instead of curation. Furthermore the resistance to the inhibitor arises inmost caseswith-
in two ﬁrst years of therapy. A thorough investigation of the signalling pathways activated by themajor PDGFRA
and KIT mutants encountered in the GIST landscape allowed to identify striking differences between the two
receptor tyrosine kinases. PDGFRA mutants were not responsive to their ligand, PDGFAA, and displayed a high
constitutive kinase activity. In contrast, all KIT mutants retained, in addition to their constitutive activation, the
ability to be stimulated by their ligand. Kit mutants displayed a lower intrinsic kinase activity relative to PDGFRA
mutants, while the KIT Exon 11 deletion mutant exhibited the highest intrinsic kinase activity among KIT mu-
tants. At the transcriptomic level, the MAPK pathwaywas established as the most prominent activated pathway,
which is commonly up-regulated by all PDGFRA and KIT mutants. Inhibition of this pathway, using the MEK
inhibitor PD0325901, reduced the proliferation of GIST primary cells at nanomolar concentrations. Altogether,
our data demonstrate the high value of MEK inhibitors for combination therapy in GIST treatment and more
importantly the interest of evaluating the SCF expression proﬁle in GIST patients presenting KIT mutations.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Gastro-intestinal stromal tumors (GIST) represent the most com-
mon mesenchymal neoplasm of the gastrointestinal tract. They arise
from the interstitial cells of Cajal and are found essentially in the stom-
ach (60% of the cases), in the small intestine (25%) but also in rectum,
oesophagus and other locations outside the gutwall [1]. GIST aremainly
due to mutations in KIT (75–85%) [1] or PDGFRA (10%) genes [2]. KIT
and PDGFRA are type III receptor tyrosine kinases (RTKs), composed
of three regions: (i) an extracellular domain responsible for ligand bind-
ing; (ii) a single transmembrane region with a juxtamembrane (JM)
domain responsible for the kinase auto-inhibition properties; and (iii)
a cytoplasmic domain that carries the kinase activity [3,4]. In the non-
activated conﬁguration, the JM domain blocks the kinase in a closed
conformation impeding ATP molecules to access the catalytic site.
After ligand binding, the wild type (WT) receptor dimerizes and tyro-
sine residues within the juxtamembrane domain are phosphorylated
[3]. This induces conformational changes and releases the inhibitorywane).
. This is an open access article underfunction of this region towards the cytoplasmic domain [4]. Finally in-
termolecular phosphorylation at tyrosine residues serves as docking
sites for SH2 domain containing molecules for further downstream
signaling, which leads essentially to the activation of MAPK and PI3K
pathways [4].
Mutations responsible for GIST occur mainly in the JM domain for
KIT and in the kinase domain for PDGFRA, leading to constitutively acti-
vated receptors [2]. The nature of themutation plays such an important
role for the treatment schedule that the ESMO recommendations in-
clude a systematic molecular analysis in the diagnosis of GIST [5]. If sur-
gery remains the treatment of choice for resectable tumors, adjuvant
therapy is highly recommended for intermediate and high risk patients
since N50% of patients relapse even after complete tumor resection [6].
In case of KIT Exon 9 or PDGFRAD842Vmutations that confer resistance
to imatinib, it is recommended either to start with high doses of imatin-
ib or to switch to the second line therapy sunitinib [5]. Both drugs target
the receptor tyrosine kinases themselves, competingwith ATP for bind-
ingwithin the catalytic site. In addition to the primary resistance of cer-
tain types of mutations to imatinib, a appears frequently within the two
ﬁrst years of therapy as a result of the acquisition of secondary muta-
tions within the kinase domain of the receptor [7]. Since the landscapethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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opment of new generation of RTK inhibitors is not expected to cope
with this issue. Therefore, the discovery of new targets for GIST therapy
is essential. Hence we propose a thorough comparison of the signalling
capacities, proffered by the main mutations found in GIST patients, in a
homogenized background in order to identify common druggable
targets.
2. Material and methods
2.1. Cell culture
The 293FR host cell line was generated fromHek293 cells by the co-
transfection of the Flp-In™ target site vector (pFRT/lac Zeo, Invitrogen)
and Tetracyclin repressor (pcDNA™6/TR, Invitrogen) as previously re-
ported [8]. KITmutant expressing cell lineswere generated by the trans-
fection of the Flp recombinase expression plasmid (pOG44, Invitrogen)
together with the transgene expression plasmid (pcDNA5/FRT/TO-
based, Invitrogen). Stably transfected cells were then selected and
cultivated in the presence of 100 μg/ml Hygromycin and 10 μg/ml
Blasticidin. Experiments were conducted under serum reduced (1%)
conditions for 11 h and for additional 3 h under serum free (0% FBS)
conditions using 5 ng/ml doxycycline (Sigma), unless differently stated
in the ﬁgure legends. The stimulation of KIT and PDGFRA expressing
cells was performed with SCF (100 ng/ml) and PDGF-AA (100 ng/ml),
respectively (Immunotools).
GIST primary cell line GIST882 [9], presenting a homozygous mis-
sense mutation in KIT exon 13, and GIST48, a homozygous primary
exon 11missensemutation and a secondary heterozygous exon 17mis-
sensemutationwere generously provided by Dr. Sebastian Bauer (WTZ,
Essen) and cultivated in RPMI and IMDM, respectively with 15% FBS in
humidiﬁed atmosphere containing 5% CO2. PD0325901 and XL-184
(Selleck Chemicals) were added to the medium 24 h after cell seeding
for 30 h at the indicated concentrations. The stimulation of primary
cell lines was performed after 6 h starvation to a ﬁnal concentration
of 100 ng/ml SCF. Cell viability was assessed with PrestoBlue
(Thermoﬁscher) in 96 well plate format following the manufacturer's
recommendations. The ﬂuorescence was monitored using the
CLARIOstar microplate reader (BMG LABTECH).
2.2. Mutagenesis
KIT wild type cDNA was reverse transcribed from Mel501 RNAs
(cells kindly provided by R. Halaban, [10]) and cloned into pCDNA5/
FR/To plasmid after insertion of AscI and SgraI restriction sites by PCR.
Plasmid was sequenced and compared to the c-KIT variant 2 mRNA se-
quence (NM_001093772.1). Two mutations were identiﬁed and ﬁxed
using Quik-change site-directed mutagenesis KIT (Stratagene) follow-
ing the manufacturer's recommendations. The single point mutation
V559D was prepared using the same procedure, while KIT Ex9 duplica-
tion mutant (AY502–503) and KIT Ex11 deletion mutant (553–557)
were prepared by Life Technologies using GeneArt™Gene Synthesis.
All plasmids were sequenced prior transfection to 293FR cells.
2.3. Flow cytometry analysis
Cell surface and total protein expression of KIT wild type and mu-
tants were analyzed by ﬂow cytometry using a FACS CantoII Instrument
(Becton Dickinson, Heidelberg, Germany). 105 cells were harvested in
the presence of PBS/10 mM EDTA and then washed with FACS-buffer
(PBS/5%FCS/0.1%NaN3). Afterward, the cells were either directly incu-
bated with 10microL KIT primary antibody (anti-CD117-APC conjugat-
ed; C7244; Dako, Belgium) for cell surface expression, or ﬁrst incubated
with 0.1% saponin permeabilizing buffer prior KIT antibody incubation
for total KIT expression. The speciﬁcity was controlled using anisotype-matched/ APC conjugated antibody (IgG1 kappa; ×0968,
Dako, Belgium).
2.4. Model building and reﬁnement with CHARMM
Since the kinase domain of KIT is located in the cytoplasmic region,
the extracellular region was removed from the model building and the
kinase insert region (residues 693 to 755) was replaced by Glycine res-
idues. The initial models of KIT regions were built by homology model-
ing using MODELER9v7 on Linux based operating environment based
on the crystal structures (PDB ID: 2EC8 and 2E9W) as templates. The
primary 3-dimensional structure of KIT WT model was further im-
proved by using energy minimization, followed by equilibration
methods both in a vacuum and in an implicit membrane with implicit
water solvation methods (EEF1) with CHARMM35 parameters. Finally,
20-ns molecular dynamics (MD) simulations were run with Langevin
dynamics with a time step of 2 fs.
2.5. Western blot analysis
Cell lysis was performed on ice, using 1× Laemmli buffer. Proteins
were subjected to SDS-PAGE, transferred to a polyvinylidene diﬂuoride
membrane (Roth) and then probed with the respective antibodies. The
last are listed in the corresponding “Data in Brief article” [11]. Signals
were detected on a Fusion-FX7 chemiluminescence detection device
(Vilber) using a home-made ECL (Enhanced ChemiLuminescence) solu-
tion [12]. Signal intensities were quantiﬁed using the Bio1D analysis
package (Vilber).
2.6. Microarray analysis
293FR cells expressing KIT-WT, KIT Ex11 deletion mutant and KIT
Ex9 mutant were treated with 5 ng/ml doxycycline and 100 ng/ml SCF
for 21 h in DMEMwith 1%FCS. Cells were then starved for 3 h (without
FCS) and further stimulated with SCF. Gene Expression analysis was
performed using GeneChip Human Gene ST 2.0 arrays (Affymetrix).
The raw data in the form of Affymetrix CEL ﬁles were imported into
Partek® Genomics Suite™ software (Partek GS). The Robust Multichip
Average (RMA)with GC correction was applied to the data set resulting
in expression values for Affymetrix transcript clusters. Quality control
and data normalization were performed as previously reported [13,
14]. We focused on differentially expressed genes (DEG) across the
mutants comparing them with non-stimulated KIT-WT. To exclude
non-relevant lowly expressed transcript clusters, only those showing
log2 expression above 4.5 were considered for further analysis.
Transcript clusters were further summarized in order to obtain a single
expression value for each gene in each experiment. The differentially
expressed genes were statistically evaluated by two-factor linear
model with empirical Bayes statistical approach using limma package
of R/Bioconductor [15]. In order to correct for the false discovery rate
(FDR), the Benjamini & Hochberg step-up method correction was ap-
plied. Probe-sets with FDR b0.05 and absolute fold change N0.5 were
considered to be signiﬁcantly differentially expressed (DEGs). Microar-
ray data are available in the ArrayExpress database (www.ebi.ac.uk/
arrayexpress) under accession number E-MTAB-4548.
2.7. Rank-Rank analysis
In order to compare the different KIT mutants and wild-type signal-
ling without any pre-deﬁned cutoffs, we used the nonparametric rank-
rank geometric overlap analysis (RRHO) [16] to identify the statistically
signiﬁcant overlap between the gene signatures. The probe sets were
ﬁrst ranked based on their signed log-transformed p-values of ANOVA
results to compare between the subgroups and the control (non-stimu-
lated wild-type KIT). The results of the analysis are represented as a
group of two plots: 1. RRHO heat map. The heat map value, visualized
Fig. 1. KIT expression in the different KIT mutants. Protein expression was achieved by
adding 5 ng/ml doxycycline to the medium for 14 h. a.Membrane KIT expression in KIT
WT, KIT V559VD, KIT Ex9, KIT Ex11 was analyzed by ﬂow cytometry. Histograms
represent the number of cells as a function of the ﬂuorescent intensity of KIT staining by
an APC-conjugated anti-KIT antibody. b. Total KIT expression observed in KIT mutants
(i.e., plasma membrane and intracellular staining). In both graphs, 293 non infected cells
and isotype control staining were used as controls and are both represented by the gray
solid histogram.
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hypergeometric p-value for the likelihood of presenting the observed
degree of overlapped number of genes between both rank thresholds.
The rank scatter plot represents the overlap between two signatures.
Spearman rank correlation coefﬁcient (rho) was calculated between
the two compared gene signatures as previously done [8].
2.8. Quantitative PCRs
mRNAs for qPCRs were extracted, as for micro-array analysis,
and used as templates for the cDNA synthesis with the high capacity
cDNA reverse transcription KIT (Applied Biosystems) following the
manufacturer's recommendation. Quantiﬁcation was performed using
ABsolute Blue QPCR SYBR Low ROX (Thermoscientiﬁc) on the AB7500
FAST PCR system (Applied Biosystems) following the MIQE guidelines
[17]. Reference genes were selected using the Genorm software [18] in-
cluded in the Qbase package (Biogazelle) used for the data analysis.
Primers sequences are listed in Table 2 in [11].
3. Results
3.1. Selection of GIST mutations included in the present study
In the COSMIC database [19], about 3200 GIST samples are currently
registered. KIT mutations represent 75%, PDGFRA 21% and WT 4% of all
gastro-intestinal stromal tumors (Table 1), which is in line with large
cohort studies previously published [1,20–22]. In this study we propose
comparing the signalling features derived from the main KIT and
PDGFRA mutations identiﬁed in GIST (Table 1). Therefore, we selected
two types of mutation in KIT Exon 11, representing N62% of GIST, and
onemutation in Exon 9, accounting for about 10% of GIST. Furthermore,
two PDGFRA mutations (D842V and D842Y) within the kinase domain
(15% of GIST) and one within the juxtamembrane domain (V561D)
(3% of GIST) were included in the study. We took advantage of the re-
cently implemented “in vitro” model where the above mentioned
PDGFRA mutants were successfully investigated in an isogenic back-
ground [8]. We stably transfected Hek293/FR cells with different KIT
constructs cloned in PCDNA5/To plasmid, namely KIT WT, KIT Ex9 (du-
plication AY 502–503), KIT V559D and KIT Ex11 delmutant (deletion of
residues 553 to 557). PDGFRA mutants are included in this study for
comparison purpose as they were deeply investigated previously [13].
3.2. KIT protein localization changes according to the mutation status
First, RNA and protein expression levels were assessed in the stably
transfected cell lines. Adding doxycycline to the culture medium en-
hances KIT expression by a factor 100 and comparable mRNA expres-
sion levels were observed for all mutants (Fig. 1a in [11]). However,
we could identify somedifferences in protein expression levels between
KIT WT, KIT V559D and KIT Ex11, KIT Ex9 (Fig. 1b in [11]). Such a dis-
crepancy between mRNA and protein expression levels was previously
observed between wild type and PDGFRA mutants, and was linked to
the protein activity [14]. Next we analyzed KIT surface expression forTable 1
Mutants investigated in this study with their incidence according to the COSMIC database.*
Genes Domains Exon
Percentage in GIST
patients according
the COSMIC databa
PDGFRA Kinase 17 15.1
Juxtamembrane 12 3.6
KIT Juxtamembrane 11 62.8
Extra-cellular domain 9 9.6
⁎ After removal of the unknown mutation (23% of all GIST present in the database, includingthe different mutants by ﬂow cytometry (Fig. 1a). KIT Ex9 mutant
displayed the highest cell surface expression, followed by KIT WT, KIT
Ex11 deletion mutant and KIT V559D. The ratio of surface (Fig. 1a) to
total KIT expression (Fig. 1b) indicates the almost exclusive presence
of KIT WT at the surface, while about 70% of KIT Ex9 is found at theto
se* Mutations
Percentage of the investigated
mutation among the mutations
found within the exon
D842V 69.9
D842Y 2.7
V561D 27.3
V559X 13.1
Del including res. 553–557 46.1
Duplication 502–503 AY 86.1
WT).
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tion, KIT surface expression decreases drastically for all KIT proteins
(Fig. 2 in [11]). Furthermore, total protein expression decreased by
N3.5 fold for theWT protein and by 1.5 vs. 1.2 fold for Ex9 and Ex11mu-
tants, respectively (Table 1 in [11]).
KIT occurs either as a complex glycosylated high molecular weight
protein of 145 kDa (HMW), or as a high mannose decorated form
with a lowermolecularweight of 125kDa (LMW) [23]. KITWT ismainly
expressed as HMW, which is a non-phosphorylated protein (Fig. 2a).
Upon SCF addition, KIT is rapidly phosphorylated and subsequentlyFig. 2. Signalling capacities of GISTmutants compared to PDGFRA andKITWT signalling. Cellswe
were starved 3 h prior harvesting and ligand stimulationwas performed 10min before cell lysis
representative Western Blots from 3 biological replicates. Counter stains are provided as contr
single point mutant KIT V559D signalling. Phosphorylation of PDGFR (Y849), KIT(Y703), PLC
was monitored by Western blot analysis with the respective antibodies. b and c. Signalling
PDGFR (Y849), KIT(Y703), PLCγ (Y783), STAT1(Y701) , STAT3 (Y705), STAT5 (Y794), MEK1/
analysis with the respective antibodies. d. Signalling from SCF stimulated GIST primary cel
Phosphorylation of KIT (Y703), AKT (Ser473) and ERK1/2 (T202pY204) was monitored by wesdephosphorylated and degraded (Figs. 1b and 3a in [11]). The JM do-
main mutants, KIT V559D (Fig. 2a) and KIT Ex11, are present in both
HMW and LMW forms that are constitutively phosphorylated, while
KIT Ex9 is present in both forms, where the HMWform is phosphorylat-
ed (Fig.2b).
In summary, contrasting protein expression is observed in stable cell
lines expressing KIT WT or KIT mutants in the human Hek293 cells
although they display similar KIT mRNA levels. KITWT and KIT Ex9 dis-
play mainly HMW protein present at the cell surface, while KIT Ex11
displays mainly the LMW form, which is retained in the intracellularre cultivated inDMEMand protein expressionwas induced for 14 h inDMEM1% FCS. Cells
, with PDGFAA and SCF (at 100 ng/ml) for PDGFR and KIT proteins, respectively. Figures are
ol. a. Signalling derived from stimulated KIT and PDGFRAWT receptors are compared to
γ (Y783), STAT3 (Y705), MEK1/2 (Ser217/221), AKT (Ser473) and ERK1/2 (T202pY204)
from stimulated KIT and PDGFRA mutant receptors are compared. Phosphorylation of
2 (Ser217/221), AKT (Ser473) and ERK1/2 (T202pY204) was monitored by western blot
l lines GIST48 and GIST882 for the indicated time points, after 6 h' starvation (0%FCS).
tern blot analysis with the respective antibodies.
Fig. 3.Molecular dynamics simulation of KITWT and KIT mutants. a. 3D structures of KITWT andmutants before (left panels) and after stimulation (right panels). Important residues for
ATP recognition are represented as red sticks and highlighted in the right insert at the top of the Figure. The two lobes of the kinase domain are schematically represented by blue circles
and the Juxtamembrane domain by in yellow.Open and closed conformationsderived from the ability of ATPmolecules to enter (OPEN) ornot (CLOSED) the catalytic site of the enzyme, as
described previously [50] b. Backbone RMSD versus time plot during the 20 nsmolecular dynamics simulation for KITWT (red), KIT V559D (blue) and KIT Ex11 deletion mutant (green).
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weak KIT expression. Upon SCF addition, KIT WT is rapidly phosphory-
lated and degraded. The mutant proteins are constitutively phosphory-
lated and redirected to the cytosol after stimulation, where their
degradation is less pronounced compared to the WT protein.
3.3. Signalling characteristics
Type III receptor tyrosine kinases conventionally activate MAPK and
PI3K/Akt pathways upon ligand stimulation [3,24]. We compared the
activation of these pathways before and after ligand stimulation be-
tween PDGFRA and KIT wild types to their respective GIST mutants. As
indicated in Fig. 2a, theWT receptors are only phosphorylated upon ad-
dition of their respective ligands, which induces the downstream phos-
phorylation of key kinases for PI3K and MAPK pathways activation,
namely Akt and Erk1/2. The introduction of the point mutation V559D
in KIT initiates the expression of a constitutively phosphorylated pro-
tein, which exhibits a weak constitutive Akt and Erk1/2 phosphoryla-
tion. The induction of the conventional KIT regulated pathways is
comparable to the wild type protein after SCF addition. Constitutive
Akt activation was similar in intensity for all PDGFRA, KIT Ex9 and KIT
Ex11 mutants (Fig. 2b). In contrast, the constitutive Erk1/2 activation
was stronger for PDGFRA mutants, compared to KIT mutants. The
MAPK/ERK activation required SCF stimulation to reach the activation
level observed for PDGFRA mutants. PLCγ activation was found to be
PDGFRA speciﬁc since neither KIT WT nor KIT mutants was able to
induce the phosphorylation of PLCγ (Fig. 2c), regardless of the SCF stim-
ulation. Another striking difference between KIT and PDGFRAWT stim-
ulations resides in the kinetics of their activation (Fig. 3 in [11]). While
the stimulation of PDGFRA by PDGFAA induces a sustained Akt and
Erk activation for up to 48 h, stimulating KIT by SCF induces a rapid
but transient (30–45 min) activation of these pathways. The activation
of STAT (signal transducer and activator of transcription) was observed
for none of the investigated time points, neither for PDGFRA nor for KIT
WTproteins (STAT3 is shown as representative STAT factor in Fig. 2a). In
contrast, the PDGFRAmutantswere strong activators of the three inves-
tigated STAT species; namely STAT1, STAT3 and STAT5 (Fig. 2c and
[13]). KIT Ex11 deletion mutant had an intermediate STATs activation
capacitywhereas KIT Ex9mutantwas identiﬁed as aweak STATs activa-
tor (Fig. 2c). We observed that ligand addition increased the activation
of STAT species for KIT Ex9 mutant (Fig. 3 in [11]). However, nuclear
translocation (Fig. 4a in [11]), required to obtain an efﬁcient transcrip-
tion factor activity, was exclusively detected for KIT Ex11 deletion
mutant. This indicates its ability to elicit an efﬁcient induction of
STAT- dependent genes (Fig. 4b in [11]). Interestingly, the primary
GIST cell line GIST48, exhibiting a homozygous mutation in KIT Ex 11,
was also responsive to SCF stimulation (Fig. 2d). A weak response to
SCF was noticed for GIST882 that harbors a KIT Ex13 homozygous mu-
tation. A 1.5 to 2 fold increase in KIT and Akt phosphorylation occurs
fewminutes after stimulation. The reasons for theweak SCF stimulation
observed for GIST882 could not be identiﬁed, however we may specu-
late that this is due to the higher endogenous expression of SCF mea-
sured in GIST882 relative to GIST48 (data not shown). Thus, GIST882
signalling may be already at its maximal intensity due to the endoge-
nous SCF stimulation. Unfortunately, both cell lines did not tolerate a
long term FCS starvation, impeding us to investigate the effect of SCF si-
lencing on GIST cells proliferation (data not shown).
In conclusion, the point mutant V559D has a weak intrinsic kinase
activity, more similar to KIT WT than to the other mutants, except for
the constitutive phosphorylation of the receptor. The three PDGFRAmu-
tants exhibit a quite strong intrinsic kinase activity regardless of ligand
stimulation. The kinase activity of the KIT mutants is, qualitatively and
quantitatively, more diverse. Only KIT Ex11 deletion mutant is an efﬁ-
cient STAT activator. The activation of Erk1/2 by KIT Ex9 is more tran-
sient when compared to KIT Ex11 deletion mutant, whereas the Akt
activation was more sustained for all stimulated KIT mutants. Moreimportantly, all KIT mutants were responding to their natural ligand
by an increase in PI3k/Akt and MAPK signalling intensities, including
the primary cell line GIST48.
3.4. Molecular dynamics simulation
In order to elucidate the reasons for the differences in signalling ca-
pacities between the point mutant KIT V559D and the deletion mutant
within the same exon, we built the respective 3D models starting from
the crystal structures available for KIT WT protein (see Material and
Methods part for model building details). The inhibitory loop formed
by the juxtamembrane domain is released by the two types of mutation
(Fig. 3a). This allows ATP molecules to reach the catalytic site located
within the cleft separating the two lobes of the kinase, which justiﬁes
the constitutive phosphorylation of these receptors. We compared the
ability of the two KIT Exon 11 mutants to accommodate ATP within
the catalytic sites of the kinase. For that, the distance between the ATP
binding residues, indicated as red sticks in Fig. 3a, was assessed.
Glutamic acid 640 interacts with the side chain of Lysine 623, which
forms a bridge with the ATP molecule while the DFG motif (D810-
F811-G812) binds the ATP-linked Mg2+ ions [25]. The results of 20 ns
molecular dynamic simulations are reported in Fig. 3b, showing that
the deletion mutant is more ﬂexible than the point mutant, which is
in equilibrium between an open and a closed conformations. This
could point towards a weaker stability of the point mutant V559D,
enforced in a constant open and active conformation that is quickly de-
graded and recycled.
3.5. Impact of the different GIST mutations on global gene expression
Nextwe investigated the transcriptional changes induced by the dif-
ferent mutations usingmicro-array analyses comparing the global gene
expression proﬁles of KIT WT, KIT Ex9 and KIT Ex11 deletion mutant
after ligand stimulation. The background expression level was obtained
from KITWTwithout stimulation. Due to the weak signalling capacities
of KIT V559D, this mutant was excluded from this analysis and gene ex-
pression levels were, when required, assessed by quantitative PCR. The
global gene expression changes, derived from the PDGFRA mutants,
were retrieved from our previous analysis [8]. We ﬁrst compared the
overall gene expression signature of KIT mutant and KIT WT by means
of a rank-rank hypergeometric overlap (RRHO) analysis [16] allowing
a comparison without the application of any cutoff. The genes lists
were ranked according to their p-value and the signiﬁcance of the over-
lap between the two lists was calculated while stepping through the
two lists of genes (Fig. 4a). The similarity was highest between KIT
Ex9 and KIT Ex11 mutants stimulated with SCF for 24 h. However, the
similarity between these two KITmutants is far from that observed pre-
viously between the three PDGFRA mutants [8]. The spearman correla-
tion obtained for the PDGFRA mutants comparison was close to 0.7
against 0.3 for the KIT mutants.
In order to identify a common GIST signature, we compared the dif-
ferentially expressed genes (DEG) common to KIT mutants (KIT Ex11
and KIT Ex9, both stimulated with SCF) and the previously proposed
PDGFRA GIST mutants signature ( [13] and Fig. 4b). We identiﬁed 140
genes, which were commonly de-regulated in all the investigated GIST
mutants. Functional analysis of this GIST signature with KEGG pathway
[26] reveals enrichment of “sprouty familymembers” and of “MAPK sig-
nalling pathway” related genes (Table 2). The regulation of SPROUTY
family members, negative feedback regulators of RTKs, was validated
by qPCR for all mutants (data not shown). Interestingly, SPRY4 was
identiﬁed as a candidate for targeted therapy in GIST with oncogenic
Kit mutation [27]. Thus, evaluatiing the expression level of other
sprouty family members could be highly valuable for all non WT-GIST.
More than half of the Top25 GIST regulated genes (Table 3),
including the sprouty familymembers, belong toMAPKpathway signal-
ling. The transcription factor ETV1, recently described to promote
ab
Fig. 4. Biological response of KIT mutant proteins differs greatly. a. RRHO heatmaps (upper row) and rank-rank scatter plots (lower row) for the comparison of stimulated KIT WT and
oncogenic KIT proteins. The compared gene lists were ranked according to the ANOVA p-values attributed to the differentially expressed genes using non-stimulated KIT WT as
control. The top differentially expressed genes are thus located at the lower left corner of the graph. For the heat maps, the range of -log10 - transformed hypergeometric p-values are
indicated in the color scale bar. High intensity signals (red) indicate the highest overlap in the lists above the current sliding rank threshold (between the rank 1 for both lists at the
bottom left corner and the colored point on the map). b. establishment of common GIST signature, including PDGFRA [8] and KIT DEGs. 114 genes are commonly regulated by all
investigated GIST mutants.
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PEA3 familymembers, ETV1, ETV4 and ETV5, are highly up-regulated in
all GISTmutants. The up-regulation of theMAPK pathway related genes
is constitutive for all the mutants, but further increased for KIT EX9 andTable 2
Functional classiﬁcation for commonly regulated genes by all GIST mutants.
Term Genes
SPROUTY family members SPRY2, IL12A, SPRED2, IL6R, SPRED1, SPRY4
MAPK signalling pathway DUSP5, FOS, DUSP1, NR4A1, GADD45B, GADD45A,
Circadian rhythm PER2, BHLHE40, CRY1
p53 signalling pathway PMAIP1, GADD45B, SESN2, GADD45AKIT Ex11 mutants upon SCF stimulation (Fig. 5). Interestingly, some
markers proposed for GIST diagnostic/prognosticwere identiﬁedwithin
the GIST signature (Table 4). The up-regulation of these potential GIST
markers in our “in vitro model” implies that their regulation path isCount % P-Value FDR
6 4.3 1.20E-02 2.10E-01
DDIT3, TGFB1 8 5.7 9.40E-03 2.40E-01
3 2.1 5.90E-03 2.90E-01
4 2.9 2.30E-02 2.90E-01
Table 3
Top 25 DEG common in PDGFRA and KIT mutants.
Ratio KIT Ex11 deletion
mutant with SCF vs KIT WT0
Ratio PDGFRΑ V561D
vs PDGFRA WT0
EGR1 20.4 15.9
GPR50 17.9 11.2
ARC 6.4 6.7
FOSL1 6.2 3.0
GPR3 6.1 2.3
CHAC1 5.7 2.9
SERPINB2 5.6 6.0
TNFRSF12A 5.6 4.4
TFPI2 4.9 4.5
ETV4 4.9 2.0
ETV5 4.9 9.5
FOS 4.8 8.3
GADD45B 4.8 2.9
SPRED1 4.3 2.6
SESN2 4.2 2.6
EGR3 4.1 7.3
EPHA2 4.1 3.1
TGFB1 3.5 2.2
CSRNP1 3.5 3.0
ETV1 3.4 2.2
DDIT3 3.3 1.5
SPRY4 3.2 1.7
SPRY2 3.1 2.3
STC2 3.1 1.5
ZFP36 3.1 3.6
NAALAD2 0.6 0.6
KBTBD10 0.6 0.6
The genes that are down regulated in GIST primary cell lines when applying the MAPK
pathway inhibitor PD0325901 are indicated in bold.
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lights their interest as GIST diagnostic markers. Remarkably, 4 out of 5
may be linked to MAPK pathway.
Since KIT Exon 11 deletion mutation is associated with poor out-
come [29], we also investigated the KIT Ex11 speciﬁc gene signature,
comparing KIT Exon 11 deletion mutant regulated genes to other GIST
mutants (PDGFRA mutants and KIT Exon 9). 277 genes (Table 3 in
[11]) were differentially expressed in KIT Ex11 deletion mutant only.
Genes associated with “cell cycle” and “insulin signalling pathway”
were found to be enriched by KEGG pathway analysis. The role of the
genes speciﬁcally induced by the mutants Kit Ex 11 in GIST progression
will be the subject of further investigation.3.6. Effect of MAPK inhibitor on the proliferation of GIST primary cells
SinceMAPK signalling axis was found to be a pillar in the GIST signa-
ture, we though to test the effect of MAPK inhibitor on GIST primary cell
growth. For this purpose, we used a speciﬁc MEK inhibitor, PD0325901,
already in clinical trials for different cancer types likeNSCLC or CRC [30].
We ﬁrst assessed the inhibitor speciﬁcity and dose response in two pri-
mary GIST cell lines, GIST48 and GIST882, imatinib resistant and sensi-
tive, respectively. We found that, starting at 100 nM, PD0325901
speciﬁcally inhibits ERK1/2 phosphorylation without decreasing Akt,
KIT or STATs activation (Fig. 6a). As assessed by western blot analysis,
inhibition of ERK1/2 phosphorylation was already observed 1 h after
the addition of the inhibitor and persisted for at least 30 h (data not
shown). We then investigated the viability of the GIST primary cell
lines after incubationwith theMEK inhibitor at different concentrations
and deduced the efﬁcacy of the inhibitor for each cell line. The results
(Fig. 6b for GIST882) indicate that PD0325901 decreases the cell viabil-
ity of the imatinib sensitive cell line with an IC50 of around 80 nM. We
could observe a further decrease in cell viability using the newly devel-
oped RTK inhibitor XL184 together with the MEK inhibitor PD0325901.
Investigation of the synergistic potential between the two compounds
using the CompuSyn software [31] reveals Combination Index (CI)values below 1, indicating a positive synergy between the two com-
pounds (Fig. 5 in [11]).
In conclusion, theMAPK pathway is a good target for GIST treatment
and the combination of RTK andMAPK inhibitors could help preventing
the emergence of RTK-inhibitor resistance.
4. Discussion
KITmutant signalling has been extensively investigated butmost re-
sults derived fromGIST primarymaterial [32,33], where patient speciﬁc
features make a systematic comparison quite challenging. Additional
knowledge resultedmainly from investigations on KIT D816V responsi-
ble for 90% of systemic mastocytosis [34,35]. To overcome the lack of
knowledge related to PDGFRA mutants in GIST, we recently performed
a thorough investigation of the 3 main PDGFRA mutants [8] found in
GISTs. Interestingly, the three mutants exhibited very similar signalling
properties that differ from the PDGFRA WT protein. We therefeore ex-
tended the comparison to PDGFRA and main KIT mutants detected in
GIST.
We found striking differences in protein localization and in intrinsic
kinase activities between the three investigated KIT mutants. In line
with a recent studywhere KIT V560D exhibited aweaker kinase activity
compared to the systemic mastocytosis mutant KIT D816V [36], the
point mutant KIT V559D displayed a weak intrinsic kinase activity com-
pared to Kit Ex9 or Kit Ex11mutants. Interestingly enough, the Ex11 de-
letionmutation is at the same timeassociatedwith a high risk factor [29,
37,38] and known to be a good responder to imatinib treatment [39]. In
the present study we propose some insights into this apparent contra-
diction. First, comparing the structures of two KIT Ex11 mutants using
molecular dynamics simulation, we found that KIT Ex11 deletion mu-
tant exhibited a high ﬂexibility between an open and a closed confor-
mation. In contrast, Kit V559D was less ﬂexible and locked in a closed
conformation. The high ﬂexibility observed in KIT Ex11 deletionmutant
might allow imatinib to be particularly efﬁcient in patients carrying KIT
Ex11 deletion mutation. Second, we found KIT V559D unable to efﬁ-
ciently activate the STAT transcription factors. We conclude that the in-
tracellular retention in the ER/Golgi compartment observed for KIT
V559Dmutant is required, as previously observed for PDGFRA mutants
[8], but not sufﬁcient to achieve a good activation of the STAT species by
RTKs. In addition, Kit Ex11 deletionmutant exhibits the highest intrinsic
kinase activity compared to the other KITmutants andwas the onlymu-
tant able to elicit an efﬁcient STATs activation. The role and activation
status of STAT species in GIST remains largely unknown. Duensing et
al. [33] investigated the STATs activation proﬁles of 15 patients, giving
a quite heterogeneous picture. No STAT5 activation could be detected
in patient samples. STAT5 phosphorylation was indeed the most unsta-
ble and difﬁcult to observe in GIST primary cell lines: GIST882 and
GIST48. STAT3was activated in almost all patients and STAT1 activation
was found higher in Exon 11missensemutants compared to Ex11 dele-
tion mutants [33]. We could demonstrate here that activation of STATs
is part of the KIT Ex11 deletion kinase activity and could be initiated
by Kit Ex9 mutant after SCF stimulation. The role of the STAT factors in
GIST initiation and progression remains intriguing and deserves further
investigations.
In the continuous efforts to identify new targets for GIST patients,
PI3K [40,41] or Hsp90 inhibitors [42,43] were anticipated as promising
for the treatment of imatinib-resistant GIST but no FDA approval has
been delivered so far. In the present study, we showed that MAPK acti-
vation was the most prominent pathway commonly induced by all
studied GIST mutants at the transcriptional level. Interestingly, not
only ETV1 was up-regulated in all GIST mutants, but also the other
members of the PEA3 family, ETV4 and ETV5. ETV1 was recently identi-
ﬁed as a key transcription factor for GIST development [28,44] and it ap-
pears now mandatory to consider the role of ETV4 and ETV5 in GIST
initiation and progression. Upon imatinib treatment, MAPK-induced
genes are rapidly but only transiently down-regulated in imatinib
Fig. 5.Up-regulation ofMAPKpathway downstream genes by PDGFRA and Kitmutants. mRNA expression level of ETV1, ETV4, ETV5 and egr1 in KIT and PDGFRAWT andmutants. Protein
expression was induced by 5 ng/ml doxycycline for 24 h, cells were starved 3 h before harvesting. KIT expressing cells were stimulated with 100 ng/ml SCF for either 30 min or 24 h.
PDGFRA WT expressing cells were stimulated with 100 ng/ml PDGFAA for either 30 min or 14 h. n= 3, Mean ± SD.
Table 4
Potential GIST markers conﬁrmed by our study to be KIT and PDGFRA dependent.
Marker/ possible targets in GIST Reference Gene identiﬁed by the present work
Actin [51] ACTBL2
Sonic hedgehog pathway [52] HHIP, KDM6B
ETV1 [53,54] ETV1, ETV4, ETV5
KCTD10 (ubiquitin-protein
transferase activity)
[55] KCTD12, KCTD13
RBPMS2 [56] RBPMS2
Spry4 [27] SPRY4, SPRY2, SPRED1, SPRED2
146 C. Bahlawane et al. / Cellular Signalling 29 (2017) 138–149sensitive cells (Fig. 6 in [11]). A recent study [45] proposed that a FGFR-
mediated reactivation of the MAPK pathway was responsible for the
transient character of imatinib treatment. Therefore, combining imatin-
ib and MAPK inhibition could reduce the MAPK reactivation and de-
crease the risks of developing resistance. A clinical trial phase Ib/II is
currently testing the efﬁciency of such a combination usingMEK162 to-
gether with imatinib (NCT01991379) [44].We identiﬁed PD0325901 as
a very efﬁcientMEK inhibitor, able to abolishMAPK activation starting a
concentration of 100 nM in both imatinib resistant and sensitive GIST
cells for a long period of time, which is not achieved by imatinib alone.
Our data support the development of combination therapy to treat
Fig. 6. Inhibition of MAPK signalling by PD0325901 in GIST primary cell lines. a.Western
blot analysis indicating the phosphorylation status of KIT, STAT5, Akt and Erk in GIST
primary cell lines GIST882 and GIST48 after treatment with MEK inhibitor PD0325901
at different concentrations. b. GIST882 viability as determined by PrestoBlue after
treatment with various doses of RTK inhibitor (XL-184) and MEK inhibitor (PD0325901)
or both of them simultaneously for 30 h. Representative data of 3 biological replicates.
Each point represents the mean of a technical duplicate.
147C. Bahlawane et al. / Cellular Signalling 29 (2017) 138–149GIST patients and overcome the development of RTK inhibitor
resistance.
Finally, the major difference between PDGFRA and KIT mutants
identiﬁed in the present study is the ligand-driven activation demon-
strated by all KIT mutants expressed in an isogenic background. While
PDGFRAmutants proffered amaximal constitutive kinase activity with-
out possible stimulation by their ligand PDGFAA, KIT mutants remained
responsive to their natural ligand, SCF. The capacity of KITmutants to be
further stimulated by their natural ligand SCF was conﬁrmed in GIST48,
which is a GIST primary cell line with homozygous mutation in KIT
Ex11. SCF activation of GIST primary cell lines was recently identiﬁed
[46,47] and authors could demonstrate an increased proliferation
upon SCF stimulation, which was associated with the heterozygous na-
ture of the mutations found in these patients [46,47]. With the present
investigation, we could in fact demonstrate that KIT mutants, at least
KIT Ex9 and KIT Ex11 mutants, may be stimulated by KIT ligand SCF.
This previously unknown feature of KIT mutants is of great importance
in the context of GIST since stem cell factor expression was foundpositive in 76% of patient samples and was associated with high risk
[46–49]. The maximal signalling capacities of KIT mutants were only
achieved upon SCF stimulation and this should be considered in future
investigations. It remains unclear how the constitutive signalling of
themutants is increased by SCF or how/whether the receptor trafﬁcking
is involved in this process. This should be investigated inmore details in
the future, including the stoichiometry of the different mutant proteins
both in presence and absence of ligand. In any case, SCF plays a major
role in the signalling properties of KIT mutants and its expression level
in patients could be helpful for prognostic purposes. In the same line,
the possibility to target SCF using antibodies should be considered in
the future.
5. Conclusion
The importance of the nature of themutations in GIST has been pre-
viously identiﬁed and efﬁciently used for diagnostic and therapeutic
purposes. We now demonstrate that constitutively active KIT mutants
retained the ability to be further stimulated by their natural ligand.
This is of high importance for the signalling properties of the kinases
and should be carefully considered in future studies investigating alter-
native therapeutic agents. We also propose the speciﬁc MEK inhibitor
PD0325901 as a promising drug in combination with Imatinib.
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